NEW YORK (GenomeWeb) – Germany's Merck KGaA reported today that its revenues for fiscal year 2015 climbed 13 percent year over year, driven by growth in its life science segment and including the contribution of Sigma-Aldrich.
Sales for the life science segment jumped 25 percent year over year to €3.36 billion ($3.71 billion) from €2.68 billion. Within that segment, the company's process solutions business had sales of €1.43 billion, while sales for its lab solutions business were around €1.20 billion, and revenues for the bioscience business area were €450 million.
According to the firm, the segment had nearly 7 percent organic growth, while currency effects added 8 percentage points, and the acquisition of Sigma-Aldrich added around 10 percent to the sales growth.
"With the acquisition of Sigma-Aldrich, the biggest takeover in our corporate history, we have become one of the leading players in the global life science industry," Karl-Ludwig Kley, chairman of the executive board of Merck KGaA, said in a statement. "We can now offer our customers a broader product portfolio than before."
The company noted that the consolidation of Sigma-Aldrich on Nov. 18, 2015, boosted its life science sales by €279 million for the year.
Sales for the firm's healthcare business segment increased around 5 percent year over year to €6.9 billion from €6.6 billion in 2014.
Overall, Merck KGaA reported revenues of €12.84 billion in FY 2015, up 13 percent from sales of €11.36 billion in 2014.
Its net income for the year was $1.11 billion versus €1.16 billion in 2014.